AI safety researcher Roman Yampolskiy breaks down his P(doom) estimate and why he believes artificial superintelligence could be a death sentence for humanity if development keeps moving this fast. His warning isn't anti-AI — it's a case for keeping AI as a tool we control, not a replacement for human judgment.Watch the full episode: https://open.spotify.com/episode/2R7oKzVSOWTR5079TYrZsg?si=302dfca33e9f4c04

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comEpisode SummaryPaul Booth, sports nutritionist, exercise physiologist and PhD researcher in ultra-running metabolism, is back on Mikkipedia, straight from UTMB week in Chamonix, where he raced OCC and worked with elite athletes. Mikki and Paul pick up where they left off a year ago, talking about how much carbohydrate trail and ultra runners actually need. Paul shares

We were delighted to be joined by two highly experienced leaders in the biotechnology industry, Howard Berman, Ph.D., and Kia Motesharei, Ph.D.Both Howard and Kia have built impressive careers across biotechnology, capital markets, business development and strategic transactions, with a track record of helping companies navigate some of the most important stages of their growth.Howard is now CEO of ReAlta Life Sciences, where he is leading the company through an important clinical-stage period as it

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments.In a new pharmaphorum podcast, host Nicole Raleigh speaks with Jason Smith, CTO of AI and analytics at Within3, for a conversation on data-fuelled agile launches and smarter decision-making. Smith discusses alignment of cross-functional teams and fostering real collaboration and efficiency, how pharma teams can use real-time data to shape more precise and effective launch strategies,

The scarecrow watches over the field, but does it watch us back? Does it keep the birds away, or does it deter darker fiends from these haunted lands? Join Robert and Joe for a Halloween-season look at the science, culture and folklore of scarecrows.See omnystudio.com/listener for privacy information.

Michael speaks with Tim Wu, the Columbia law professor and author of The Age of Extraction, about how media and tech platforms learned to harvest our attention, why convenience is among the most powerful forces of our time, and what the easy option can take from us. They discuss:(00:00) Cold open(01:12) Selling attention, from 1833 to now(07:46) Why phones are changing human evolution(16:20) Why ads adapt to every backlash(18:00) Attention merchants vs. extractors(25:48) Easiest wins: the power of

We’re all aware – and wary – of doomscrolling. Lots of screen time can be bad for us. But what if that’s not always the case? We spoke with the author of a study that found a positive relationship between screen time and brain development in young people. This episode, we sort through what to actually worry about when it comes to screen time – and what guidelines already exist that can empower you and the kids in your life.Interested in learning more about how screen time affects your brain? Email

The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus reportmoves GLP-1 and SGLT2 drugs earlier in type 2 diabetes care, potentially from diagnosis, and prefers weight-lowering drugs for people with overweight orobesity. Lilly's ACHIEVE-4 put its oral GLP-1 pill Foundayo against insulin and met a heart-safety bar. Real-world data arrived

Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met its pivotal immune-response framework, with two serotypes clearing only a looser threshold against Merck's CAPVAXIVE—not proof of disease prevention. Deals span GE HealthCare–SOFIE and PET tracer FAPI-74, Shionogi–IntraBio and AQNEURSA in rare

Carla Rothlin joins Immune at AAI2026 to talk about her career studying inflammation regulation and how she co-founded the Global Immunotalks virtual seminar series. Host: Cindy Leifer Guest: Carla Rothlin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server TAM receptor signaling in immune homeostasis (Annu Rev Immunol, 2015) MerTk in retinal pigment epithelial cells (Sci Adv, 2023) Modifiers determine MerTk function (Elife,

You've perfected your process at the bench. Now comes the part that keeps CMC scientists up at night: will it still work at 2,000L? Right now, most teams find out the hard way, through failed runs, wasted batches, and months of delay to patients waiting on a therapy. Christian Witz believes there's a better way: use computational fluid dynamics to see how your cells will actually behave at full scale before you ever run the process, and stop treating scale-up as a guessing game. On this episo...

In this special episode, in partnership with Frontiers Science House, we launch our new Why? series by asking one of the biggest questions of our time: Why AI? Why has artificial intelligence advanced so rapidly, why does it work the way it does, and why could it fundamentally change how we think, work, and live? To explore the answers, we hear from four remarkable voices at the heart of the AI conversation: Geoffrey Hinton, Mike Wooldridge, Cristina Criddle, and Wendy Hall. Like this podcast

Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington. The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the preceden...

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

What is the state of the debate over evolution and intelligent design in the UK? And how will Discovery Institute's new Cambridge initiative impact the debate going forward? On this ID The Future, host Andrew McDiarmid welcomes fellow Scotsman Dr. Alistair McKitterick, a Consulting Fellow at the Center for Science & Culture’s Whewell Center in Cambridge and a Program Director at London School of Theology. The pair will discuss how Alistair got interested in intelligent design, his work at the

Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.

Each week, join Editor-in-Chief Brad Maron, along with cohosts Mercedes Carnethon and Jane Wilcox for the new iteration of Circulation on the Run. This week, Brad and Merci welcome our own Jane Wilcox to discuss a new article type in Circulation: Clinical Problem-Solving. She also discusses her own Clinical Problem-Solving article "When VT Storm, PET Positivity, and a Negative Endomyocardial Biopsy Collide." Then Brad and Merci speak with Associate Editor Maria Kontaridis as she discusses her

🧠 JOIN THE GIANT'S SHOULDER FAMILYBecome a YouTube Member for exclusive episodes, early access + ad-free viewing 👇https://www.youtube.com/@thegiantsshoulder/joinAlexander Beiner is the writer who volunteered as a guinea pig for the world's first extended-state DMT trial. At Imperial College London, he was one of eleven people kept on a continuous DMT drip for thirty minutes. He is a co-Executive Director of Breaking Convention, Europe's largest psychedelic conference, and the author of

In this episode of The BioHub Podcast, Ben sits down with Dr. Inder Kaul, Chief Medical Officer at Draig Therapeutics, to discuss the evolution of neuropsychiatric drug development and what it takes to translate novel neuroscience into meaningful medicines for patients.Inder brings decades of global clinical development experience, most recently playing a key role in the development of Cobenfy at Karuna Therapeutics and Bristol Myers Squibb - one of the most significant advances in schizophrenia

Lilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without a known 17p deletion. Novartis agrees to $575 million upfront for Abogen's autoimmune RNA program, and Sanofi-Regeneron expands its long-acting antibody partnership. Ovarian-cancer datasets, Mirum's hepatitis D results and uniQure's Huntington's filing show why patient populations and control groups matter. CMS